# Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Study · id `cardio:ct-nct02362646` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02362646](<https://clinicaltrials.gov/study/NCT02362646>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02362646

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT02362646. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2018-08-10 (actual). Results posted on 2019-11-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Start date: 2015-07 (registry gives no type) (ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Primary completion: 2018-08-10 (actual) (ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Completion: 2019-08-23 (actual) (ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Results first posted: 2019-11-26 (ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02362646, source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02362646-2019-11-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
- Condition: Heart Failure
- Condition: Cardiomyopathy
- Condition: Ventricular Dysfunction
- Intervention (Biological): MPC Intramyocardial Injection
- Intervention (Drug): Control Solution
- Lead sponsor: Annetine Gelijns
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Annetine Gelijns (`cardio:org-annetine-gelijns`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial (`cardio:pubmed-30912838`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c56359fbccf7b67eab471deb1c0ace86b832bf7a89113bd8b893f71b3dbf3133
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
